Back to search
FDAFDA · Food and drugs·Recall number D-0028-2026

Fasenra (benralizumab) Injection, 30 mg/mL, one single-dose pre-filled syringe, Rx only, Manufactured by: AstraZeneca AB, Sweden, Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850. NDC 0310-1730-30

Published October 22, 2025 · Recall initiated: October 8, 2025

Summary

FDA records drug Class II recall D-0028-2026, published October 22, 2025 and initiated October 8, 2025. Recalling firm: ASTRAZENECA PHARMACEUTICALS; Status: Ongoing; Reported quantity: 916 pre-filled syringes; Lot: Lot YJ0152, Expiry: 01/31/2028. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility:

What to do

Voluntary: Firm initiated · E-Mail

Get an email if FASENRA has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
FASENRA
Manufacturer
ASTRAZENECA PHARMACEUTICALS
Distributor
Nationwide in the U.S
Lot
Lot YJ0152, Expiry: 01/31/2028.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Fasenra (benralizumab) Injection, 30 mg/mL, one single-dose pre-filled syringe, Rx only, Manufactured by: AstraZeneca AB, Sweden, Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850. NDC 0310-1730-30 recalled?

Yes. FDA published recall D-0028-2026 on October 22, 2025. Reported hazard: Lack of Assurance of Sterility:

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: FASENRA.